RIL
AVTX icon

Rothschild Investment LLC’s Avalo Therapeutics AVTX Stock Holding History

Rothschild Investment LLC’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$647 Buy
+35
New +$553 ﹤0.01% 3206

Other funds holding AVTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NFT
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Rothschild Investment LLC's AVTX Position: Q2 2026 in Review

Rothschild Investment LLC opened a new position in Avalo Therapeutics (AVTX) in Q2 2026: 35 shares worth $647. The stake represents ﹤0.01% of the portfolio and ranks #3206 among its holdings.

27 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

  • Rothschild Investment LLC held 35 shares of Avalo Therapeutics worth $647 as of Q2 2026.
  • Avalo Therapeutics was a new Rothschild Investment LLC position in Q2 2026.
  • Avalo Therapeutics made up ﹤0.01% of Rothschild Investment LLC's portfolio in Q2 2026, its #3206 holding.
  • 27 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on Rothschild Investment LLC's 13F filing for Q2 2026, filed 6 Aug 2026.